Skip to main content
Diagnostic Medical Systems logo

Diagnostic Medical Systems — Investor Relations & Filings

Ticker · ALDMS ISIN · FR0012202497 LEI · 969500RKTIGCNNIKIN19 PA Manufacturing
Open in API
Filings indexed 232 across all filing types
Latest filing 2022-12-06 Legal Proceedings Report
Country FR France
Listing PA ALDMS

About Diagnostic Medical Systems

https://www.dms.com/en/home/

Diagnostic Medical Systems (DMS) specializes in the development, design, and manufacturing of medical imaging systems. The company's core focus is on digital radiology and bone densitometry. Its product portfolio includes radiography and fluoroscopy systems, mobile x-ray units, surgical C-arms, and bone densitometers. DMS is engaged in developing next-generation imaging solutions aimed at improving patient care and personalized medicine. Key development projects include new mobile and surgical imaging equipment and an advanced range of bone densitometers for diagnosing and monitoring pathologies affecting bone mineral density.

Recent filings

Filing Released Lang Actions
Révocation du plan de réorganisation judiciaire de DMS Imaging homologué le 9 février 2021
Legal Proceedings Report Classification · 99% confidence The document discusses a legal judgment from the Commercial Court of Liège concerning the revocation of a judicial reorganization plan for DMS Imaging. It details legal proceedings, court decisions, and subsequent appeal plans. This content directly relates to significant legal matters involving the company. Based on the definitions, this falls under 'Legal Proceedings Report' (LTR), as it is an update on a significant lawsuit/regulatory action (the revocation of the reorganization plan). It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general announcement of a report (RPA/RNS), but rather a specific disclosure about a legal event.
2022-12-06 French
DMS Group annonce un partenariat avec Canon Medical Systems Europe pour le développement et la distribution d'un système RF de nouvelle génération développé par DMS Imaging à partir de la technologie
Regulatory Filings Classification · 90% confidence The document announces a strategic partnership between DMS Group and Canon Medical Systems Europe regarding the development and distribution of a new RF system. This is a corporate announcement detailing a business development, not a mandatory regulatory filing like a 10-K, an earnings release (ER), or a formal capital change (CAP/SHA). It is a general business update. Since it doesn't fit the specific categories like AGM-R, 10-K, ER, CT, or DIRS, and it is a significant business announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or significant corporate news releases that aren't covered by more specific codes. Given the nature of the announcement (partnership, distribution agreement), it is a form of regulatory disclosure, even if not a specific SEC form.
2022-11-30 French
DMS Group reveals its new ambitions and presents its strategic plan: 'Imaging 2027': becoming a key player of medical imaging in Europe
Regulatory Filings Classification · 95% confidence The document is an announcement dated October 25th, 2022, detailing the company's new strategic plan called "Imaging 2027." It outlines financial objectives (turnover, EBITDA margin), strategic axes (innovation, organic growth, sector consolidation), and announces the implementation of a new strategic committee and a planned divestiture (sale of Hybrigenics shares) and a future shareholder benefit (free allocation of equity warrants). It also includes a financial calendar mentioning the 'Publication of the 2022 annual turnover' in January 2023. This content is a high-level strategic update and announcement of management/governance changes (new committee members) and corporate actions, rather than a full financial report (like 10-K or IR) or a simple earnings release (ER). It fits best under Management Reports (MDA) as it details management's strategic outlook and plans, or potentially Governance Information (CGR) due to the committee announcement, but the focus on the 5-year strategic plan and financial targets strongly suggests MDA.
2022-10-26 English
DMS Group dévoile ses nouvelles ambitions et présente son plan stratégique : ' Imaging 2027 ' : devenir un acteur incontournable de l'imagerie médicale en Europe
Investor Presentation Classification · 98% confidence The document outlines a new strategic plan for DMS Group called "Imaging 2027," detailing ambitious financial targets (revenue and EBITDA margin by 2027), strategic axes (Innovation, Organic Growth, Sector Consolidation), product development updates, management appointments (new Strategic Committee members), and a planned divestiture (DMS Biotech/Hybrigenics) and shareholder reward (free warrants). It also includes a financial agenda for 2022/2023. This content is characteristic of a major strategic announcement or investor presentation designed to communicate future direction and performance goals to the market, rather than a routine regulatory filing like a 10-K, an earnings release (ER), or a simple notice of dividend (DIV). Since it is a detailed presentation of strategy, goals, and management structure, the most appropriate classification is Investor Presentation (IP). The document length is substantial (14,222 chars), confirming it is a detailed report, not a short announcement (RPA/RNS).
2022-10-25 French
Signature d'un protocole d'accord en vue d'organiser la cession du bloc de titres détenus par DMS Group dans Hybrigenics
M&A Activity Classification · 98% confidence The document announces the signing of a Memorandum of Understanding (Protocole d'accord) between DMS Group and Hybrigenics regarding the sale of DMS Group's entire stake in Hybrigenics. This action involves a significant change in ownership structure and potential corporate control, which falls under the category of Mergers & Acquisitions (M&A) activity or a major transaction. The definition for M&A Activity (TAR) covers merger proposals or takeover bids. Since this is a definitive agreement to sell a controlling stake, it strongly aligns with the 'M&A Activity' classification.
2022-10-21 French
Chiffre d'affaires à neuf mois de 25,9 M EUR
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial update from DMS Group, detailing consolidated revenue for the first nine months of 2022. It includes comparative financial tables, analysis of business segments (Radiology, Osteodensitometry, Biotech), and management commentary on performance and outlook. It is not a full annual report, nor is it a mere announcement of a report; it contains substantive financial data and analysis for an interim period, fitting the definition of an Interim/Quarterly Report. 9M 2022
2022-10-20 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.